Expertise in
16
conditions

Dr. Daniel Morgensztern

Oncology
Washington University Cancer Center Pharmacy-South County
5225 Mid America Plz, 
Saint Louis, MO 
Clinical Trials:Currently Recruiting for 1 Trial
Expertise in
16
conditions
Washington University Cancer Center Pharmacy-South County
5225 Mid America Plz, 
Saint Louis, MO 

Overview

Daniel Morgensztern is an Oncologist in Saint Louis, Missouri. Dr. Morgensztern is highly rated in 16 conditions, according to our data. His top areas of expertise are Lung Cancer, Non-Small Cell Lung Cancer (NSCLC), Small Cell Lung Cancer (SCLC), and EGFR Positive Lung Cancer.

His clinical research consists of co-authoring 131 peer reviewed articles and participating in 37 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties

Oncology

Licenses

Internal Medicine in MO

Hospital Affiliations

Missouri Baptist Medical Center
Barnes-Jewish West County Hospital
Barnes Jewish Hospital
Memorial Hospital
Parkland Health Center

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Cox Health
  • EPO
  • PPO
Devoted Health
  • MEDICARE MAPD
  • OTHER MEDICARE
Essence Healthcare
  • INSURANCE PLAN
  • MEDICARE MAPD
Health Alliance
  • EPO
  • HMO
  • POS
  • PPO
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Highmark
  • EPO
  • HMO
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Independent Health
  • EPO
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Meridian Choice
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Premera Blue Cross
  • INSURANCE PLAN
  • MEDICARE MAPD
  • OTHER COMMERCIAL
  • PPO
Simply Healthcare
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • OTHER MEDICARE PART D
TeamCare
  • OTHER COMMERCIAL
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 15 Less Insurance Carriers -

Locations

Washington University Cancer Center Pharmacy-South County
5225 Mid America Plz, Saint Louis, MO 63129
Other Locations
Washington University
660 S Euclid Ave, Saint Louis, MO 63110

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

37 Clinical Trials

LUNGMAP: A Master Protocol To Evaluate Biomarker-Driven Therapies And Immunotherapies In Previously-Treated Non-Small Cell Lung Cancer (Lung-Map Screening Study)
LUNGMAP: A Master Protocol To Evaluate Biomarker-Driven Therapies And Immunotherapies In Previously-Treated Non-Small Cell Lung Cancer (Lung-Map Screening Study)
Enrollment Status: Recruiting
Publish Date: December 05, 2025
Intervention Type: Drug
Study Drug: Screening Platform
Study Phase: Phase 2/Phase 3
A Phase I/II Multi-site Study of Rucaparib and Pembrolizumab Maintenance Therapy in Stage IV Non-Squamous Non-Small Cell Lung Cancer After Initial Therapy With Carboplatin, Pemetrexed, and Pembrolizumab
A Phase I/II Multi-site Study of Rucaparib and Pembrolizumab Maintenance Therapy in Stage IV Non-Squamous Non-Small Cell Lung Cancer After Initial Therapy With Carboplatin, Pemetrexed, and Pembrolizumab
Enrollment Status: Terminated
Publish Date: February 12, 2026
Intervention Type: Drug
Study Drugs: Pembrolizumab, Pemetrexed, Carboplatin, Rucaparib
Study Phase: Phase 1/Phase 2
Phase I/II Study Exploring the Safety and Efficacy of Combining APL-101 With Frontline Osimertinib in Patients With EGFR-mutated Metastatic Non-small Cell Lung Cancer (NSCLC)
Phase I/II Study Exploring the Safety and Efficacy of Combining APL-101 With Frontline Osimertinib in Patients With EGFR-mutated Metastatic Non-small Cell Lung Cancer (NSCLC)
Enrollment Status: Active_not_recruiting
Publish Date: January 20, 2026
Intervention Type: Drug
Study Drugs: APL-101, Osimertinib
Study Phase: Phase 1/Phase 2
A Randomized Phase II Trial of Cabozantinib and Cabozantinib Plus Nivolumab Versus Standard Chemotherapy in Patients With Previously Treated Non-Squamous NSCLC
A Randomized Phase II Trial of Cabozantinib and Cabozantinib Plus Nivolumab Versus Standard Chemotherapy in Patients With Previously Treated Non-Squamous NSCLC
Enrollment Status: Active_not_recruiting
Publish Date: November 17, 2025
Intervention Type: Procedure, Drug, Biological
Study Drugs: Cabozantinib S-malate, Docetaxel, Gemcitabine Hydrochloride, Nab-paclitaxel, Nivolumab, Paclitaxel, Ramucirumab
Study Phase: Phase 2
A Phase 1/1b Study of CHS-388 (Formerly Known as SRF388) in Patients With Advanced Solid Tumors
A Phase 1/1b Study of CHS-388 (Formerly Known as SRF388) in Patients With Advanced Solid Tumors
Enrollment Status: Completed
Publish Date: November 10, 2025
Intervention Type: Drug
Study Drug: SRF388
Study Phase: Phase 1
A Pilot Study to Evaluate the Safety and Efficacy of Zimberelimab (AB122) in Combination With Domvanalimab (AB154) and Etrumadenant (AB928) in Patients With Previously Treated Non-Small Cell Lung Cancer
A Pilot Study to Evaluate the Safety and Efficacy of Zimberelimab (AB122) in Combination With Domvanalimab (AB154) and Etrumadenant (AB928) in Patients With Previously Treated Non-Small Cell Lung Cancer
Enrollment Status: Active_not_recruiting
Publish Date: November 05, 2025
Intervention Type: Drug
Study Drugs: Zimberelimab, Domvanalimab, Etrumadenant
Study Phase: Phase 2
A Phase II Study of Maintenance Vorolanib and Atezolizumab in Patients With Extensive-stage SCLC
A Phase II Study of Maintenance Vorolanib and Atezolizumab in Patients With Extensive-stage SCLC
Enrollment Status: Terminated
Publish Date: November 03, 2025
Intervention Type: Drug
Study Drugs: Vorolanib, Atezolizumab
Study Phase: Phase 2
Phase II Study of a Personalized Neoantigen Vaccine in Combination With Durvalumab (MEDI4736) in Extensive Stage Small Cell Lung Cancer
Phase II Study of a Personalized Neoantigen Vaccine in Combination With Durvalumab (MEDI4736) in Extensive Stage Small Cell Lung Cancer
Enrollment Status: Active_not_recruiting
Publish Date: October 22, 2025
Intervention Type: Biological, Drug, Device, Procedure
Study Drugs: Neoantigen DNA Vaccine, Durvalumab
Study Phase: Phase 2
Phase 1 Trial to Determine the Recommended Phase 2 Dose (RP2D) of M6620 (VX-970, Berzosertib) When Combined With Whole Brain Radiotherapy (WBRT) in Patients With Brain Metastases From Lung Cancer
Phase 1 Trial to Determine the Recommended Phase 2 Dose (RP2D) of M6620 (VX-970, Berzosertib) When Combined With Whole Brain Radiotherapy (WBRT) in Patients With Brain Metastases From Lung Cancer
Enrollment Status: Active_not_recruiting
Publish Date: October 08, 2025
Intervention Type: Other, Radiation, Drug, Procedure
Study Drug: Berzosertib
Study Phase: Phase 1
A Phase I Dose-Escalation Trial of Biweekly Intraperitoneal Oxaliplatin With Systemic Capecitabine and Bevacizumab Following Cytoreduction in Patients With Peritoneal Carcinomatosis From Appendiceal or Colorectal Cancer
A Phase I Dose-Escalation Trial of Biweekly Intraperitoneal Oxaliplatin With Systemic Capecitabine and Bevacizumab Following Cytoreduction in Patients With Peritoneal Carcinomatosis From Appendiceal or Colorectal Cancer
Enrollment Status: Active_not_recruiting
Publish Date: September 17, 2025
Intervention Type: Drug
Study Phase: Phase 1
A Pilot Study of Nintedanib in Molecularly Selected Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)
A Pilot Study of Nintedanib in Molecularly Selected Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)
Enrollment Status: Completed
Publish Date: June 24, 2025
Intervention Type: Drug
Study Drug: Nintedanib
Study Phase: Phase 2
Older Non-Small Cell Lung Cancer Patients (>/= 70 Years of Age) Treated With First-Line MK-3475 (Pembrolizumab)+/- Chemotherapy (Oncologist's/Patient's Choice)
Older Non-Small Cell Lung Cancer Patients (>/= 70 Years of Age) Treated With First-Line MK-3475 (Pembrolizumab)+/- Chemotherapy (Oncologist's/Patient's Choice)
Enrollment Status: Active_not_recruiting
Publish Date: June 13, 2025
Intervention Type: Other, Drug
Study Drugs: Pembrolizumab, Pemetrexed, Carboplatin
Study Phase: Phase 2
A Phase III Randomized Study of Nivolumab Plus Ipilimumab Versus Nivolumab for Previously Treated Patients With Stage IV Squamous Cell Lung Cancer and No Matching Biomarker (Lung-Map Sub-Study)
A Phase III Randomized Study of Nivolumab Plus Ipilimumab Versus Nivolumab for Previously Treated Patients With Stage IV Squamous Cell Lung Cancer and No Matching Biomarker (Lung-Map Sub-Study)
Enrollment Status: Active_not_recruiting
Publish Date: May 21, 2025
Intervention Type: Other, Biological
Study Drugs: Ipilimumab, Nivolumab
Study Phase: Phase 3
A Phase II Study of RRx-001 in Platinum Refractory/Resistant Small Cell Carcinoma, EGFR TKI Resistant EGFR+ T790M Negative Non-Small Cell Lung Cancer, High Grade Neuroendocrine Tumors and Resistant/Refractory Ovarian Cancer Prior to Re-administration of Platinum Based Doublet Regimens (QUADRUPLE THREAT)
A Phase II Study of RRx-001 in Platinum Refractory/Resistant Small Cell Carcinoma, EGFR TKI Resistant EGFR+ T790M Negative Non-Small Cell Lung Cancer, High Grade Neuroendocrine Tumors and Resistant/Refractory Ovarian Cancer Prior to Re-administration of Platinum Based Doublet Regimens (QUADRUPLE THREAT)
Enrollment Status: Completed
Publish Date: March 17, 2025
Intervention Type: Drug
Study Drugs: RRx-001, Cisplatin, Etoposide, Carboplatin, Irinotecan, Vinorelbine, Doxil, Gemcitabine, Taxane, Paclitaxel, Nab-Paclitaxel, Pemetrexed
Study Phase: Phase 2
Evaluating the Safety and Efficacy of Chemotherapy in Patients With Relapsed Small Cell Lung Cancer in Combination With Allopurinol and MycoPhenolate (CLAMP Trial)
Evaluating the Safety and Efficacy of Chemotherapy in Patients With Relapsed Small Cell Lung Cancer in Combination With Allopurinol and MycoPhenolate (CLAMP Trial)
Enrollment Status: Terminated
Publish Date: December 05, 2024
Intervention Type: Drug
Study Drugs: Mycophenolate Mofetil, Allopurinol, Irinotecan
Study Phase: Phase 1
Ramucirumab and Atezolizumab After Progression on Any Immune Checkpoint Blocker in NSCLC (RamAtezo-1)
Ramucirumab and Atezolizumab After Progression on Any Immune Checkpoint Blocker in NSCLC (RamAtezo-1)
Enrollment Status: Completed
Publish Date: July 30, 2024
Intervention Type: Drug, Procedure
Study Drugs: Ramucirumab, Atezolizumab
Study Phase: Phase 2
A Phase IB and Randomized Open-Label Phase II Study of Berzosertib (M6620, VX-970) in Combination With Carboplatin/Gemcitabine/Pembrolizumab in Patients With Chemotherapy-Naïve Advanced Non-Small Cell Lung Cancer of Squamous Cell Histology
A Phase IB and Randomized Open-Label Phase II Study of Berzosertib (M6620, VX-970) in Combination With Carboplatin/Gemcitabine/Pembrolizumab in Patients With Chemotherapy-Naïve Advanced Non-Small Cell Lung Cancer of Squamous Cell Histology
Enrollment Status: Active_not_recruiting
Publish Date: July 03, 2024
Intervention Type: Procedure, Drug, Biological
Study Drugs: Berzosertib, Carboplatin, Gemcitabine Hydrochloride, Pembrolizumab
Study Phase: Phase 1/Phase 2
A Randomized, Double-Blind, Placebo-Controlled Trial of Tomivosertib in Combination With Anti-PD-(L)1 Therapy in Subjects With NSCLC as First Line Therapy or When Progressing on Single-Agent First-Line Anti PD (L)1 Therapy
A Randomized, Double-Blind, Placebo-Controlled Trial of Tomivosertib in Combination With Anti-PD-(L)1 Therapy in Subjects With NSCLC as First Line Therapy or When Progressing on Single-Agent First-Line Anti PD (L)1 Therapy
Enrollment Status: Active_not_recruiting
Publish Date: April 30, 2024
Intervention Type: Biological, Drug
Study Drugs: Tomivosertib, Pembrolizumab
Study Phase: Phase 2
A Phase 1 Open-Label, Multi-Center First in Human Study of TnMUC1-Targeted Genetically-Modified Chimeric Antigen Receptor T Cells in Patients With Advanced TnMUC1-Positive Solid Tumors and Multiple Myeloma
A Phase 1 Open-Label, Multi-Center First in Human Study of TnMUC1-Targeted Genetically-Modified Chimeric Antigen Receptor T Cells in Patients With Advanced TnMUC1-Positive Solid Tumors and Multiple Myeloma
Enrollment Status: Terminated
Publish Date: January 24, 2024
Intervention Type: Drug, Biological
Study Drugs: CART-TnMUC1, Cyclophosphamide, Fludarabine
Study Phase: Phase 1
A Phase 1b/2 Study of Viagenpumatucel-L (HS-110) in Combination With Multiple Treatment Regimens in Patients With Non-Small Cell Lung Cancer (The DURGA Trial)
A Phase 1b/2 Study of Viagenpumatucel-L (HS-110) in Combination With Multiple Treatment Regimens in Patients With Non-Small Cell Lung Cancer (The DURGA Trial)
Enrollment Status: Completed
Publish Date: September 21, 2023
Intervention Type: Biological, Drug
Study Drugs: Viagenpumatucel-L, Nivolumab, Pembrolizumab, Pemetrexed
Study Phase: Phase 1/Phase 2
A Phase II Study of MEDI4736 (Durvalumab) Plus Tremelimumab as Therapy for Patients With Previously Treated Anti-PD-1/PD-L1 Resistant Stage IV Squamous Cell Lung Cancer (Lung-Map Non-Match Sub-Study)
A Phase II Study of MEDI4736 (Durvalumab) Plus Tremelimumab as Therapy for Patients With Previously Treated Anti-PD-1/PD-L1 Resistant Stage IV Squamous Cell Lung Cancer (Lung-Map Non-Match Sub-Study)
Enrollment Status: Completed
Publish Date: June 09, 2023
Intervention Type: Biological, Other
Study Drugs: Durvalumab, Tremelimumab
Study Phase: Phase 2
A Biomarker-Driven Master Protocol for Previously Treated Squamous Cell Lung Cancer (Lung-Map)
A Biomarker-Driven Master Protocol for Previously Treated Squamous Cell Lung Cancer (Lung-Map)
Enrollment Status: Completed
Publish Date: June 01, 2023
Intervention Type: Biological, Drug, Other
Phase Ib, Multicenter, Open Label Study of PDR001 in Combination With Platinum Doublet Chemotherapy and Other Immunooncology Agents in PD-L1 Unselected, Metastatic NSCLS Patients (ElevatION:NSCLC-101 Trial)
Phase Ib, Multicenter, Open Label Study of PDR001 in Combination With Platinum Doublet Chemotherapy and Other Immunooncology Agents in PD-L1 Unselected, Metastatic NSCLS Patients (ElevatION:NSCLC-101 Trial)
Enrollment Status: Terminated
Publish Date: August 15, 2022
Intervention Type: Drug
Study Drugs: PDR001, Cisplatin, Gemcitabine, Pemetrexed, Carboplatin, Paclitaxel, Canakinumab
Study Phase: Phase 1
Pilot Study of Hepatic Arterial Infusion Therapy in Patients With Unresectable or Borderline Resectable Intrahepatic Cholangiocarcinoma
Pilot Study of Hepatic Arterial Infusion Therapy in Patients With Unresectable or Borderline Resectable Intrahepatic Cholangiocarcinoma
Enrollment Status: Terminated
Publish Date: August 10, 2022
Intervention Type: Drug
Study Phase: Phase 1
A Phase 1b/2 Study of Tergenpumatucel-L (HyperAcute Lung) Immunotherapy in Combination With the IDO Pathway Inhibitor Indoximod and Docetaxel in Patients With Advanced Previously Treated Non-Small Cell Lung Cancer (NSCLS)
A Phase 1b/2 Study of Tergenpumatucel-L (HyperAcute Lung) Immunotherapy in Combination With the IDO Pathway Inhibitor Indoximod and Docetaxel in Patients With Advanced Previously Treated Non-Small Cell Lung Cancer (NSCLS)
Enrollment Status: Terminated
Publish Date: April 06, 2022
Intervention Type: Drug, Biological
Study Drugs: Docetaxel, Tergenpumatucel-L, Indoximod
Study Phase: Phase 1
A Phase II, Single-center, Open-label Study of Ramucirumab, Atezolizumab and N-803 After Progression on Any Immune Checkpoint Blocker in NSCLC (RAN)
A Phase II, Single-center, Open-label Study of Ramucirumab, Atezolizumab and N-803 After Progression on Any Immune Checkpoint Blocker in NSCLC (RAN)
Enrollment Status: Withdrawn
Publish Date: November 05, 2021
Intervention Type: Drug
Study Phase: Phase 2
An Open-label, Single-Arm, Phase 2 Study Evaluating the Efficacy, Safety and Pharmacokinetics of Rovalpituzumab Tesirine (SC16LD6.5) for Third-line and Later Treatment of Subjects With Relapsed or Refractory Delta-Like Protein 3-Expressing Small Cell Lung Cancer (TRINITY)
An Open-label, Single-Arm, Phase 2 Study Evaluating the Efficacy, Safety and Pharmacokinetics of Rovalpituzumab Tesirine (SC16LD6.5) for Third-line and Later Treatment of Subjects With Relapsed or Refractory Delta-Like Protein 3-Expressing Small Cell Lung Cancer (TRINITY)
Enrollment Status: Completed
Publish Date: July 30, 2021
Intervention Type: Drug
Study Phase: Phase 2
A Phase I/II Study of X-82, an Oral Anti-VEGFR Tyrosine Kinase Inhibitor, With Everolimus for Patients With Pancreatic Neuroendocrine Tumors
A Phase I/II Study of X-82, an Oral Anti-VEGFR Tyrosine Kinase Inhibitor, With Everolimus for Patients With Pancreatic Neuroendocrine Tumors
Enrollment Status: Terminated
Publish Date: July 08, 2021
Intervention Type: Drug
Study Phase: Phase 1/Phase 2
A Phase II Study of Talazoparib (BMN 673) in Patients With Homologous Recombination Repair Deficiency Positive Stage IV Squamous Cell Lung Cancer (Lung-Map Sub-Study)
A Phase II Study of Talazoparib (BMN 673) in Patients With Homologous Recombination Repair Deficiency Positive Stage IV Squamous Cell Lung Cancer (Lung-Map Sub-Study)
Enrollment Status: Completed
Publish Date: June 23, 2021
Intervention Type: Other, Drug
Study Drug: Talazoparib
Study Phase: Phase 2
A Phase II Study of Palbociclib for Previously Treated Cell Cycle Gene Alteration Positive Patients With Stage IV Squamous Cell Lung Cancer (Lung-Map Sub-Study)
A Phase II Study of Palbociclib for Previously Treated Cell Cycle Gene Alteration Positive Patients With Stage IV Squamous Cell Lung Cancer (Lung-Map Sub-Study)
Enrollment Status: Completed
Publish Date: May 27, 2021
Intervention Type: Other, Drug
Study Drugs: Docetaxel, Palbociclib
Study Phase: Phase 2/Phase 3
A Pilot Study of Pazopanib in Molecularly Selected Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)
A Pilot Study of Pazopanib in Molecularly Selected Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)
Enrollment Status: Terminated
Publish Date: July 14, 2020
Intervention Type: Drug
Study Phase: Phase 2
Pilot Feasibility Study of the Combination of a Personalized Therapeutic Anti-tumor Vaccine With Pembrolizumab and Standard of Care Chemotherapy in Squamous Non-Small Cell Lung Cancer and Extensive Stage Small Cell Lung Cancer
Pilot Feasibility Study of the Combination of a Personalized Therapeutic Anti-tumor Vaccine With Pembrolizumab and Standard of Care Chemotherapy in Squamous Non-Small Cell Lung Cancer and Extensive Stage Small Cell Lung Cancer
Enrollment Status: Withdrawn
Publish Date: April 12, 2019
Intervention Type: Procedure, Drug, Biological
Study Phase: Phase 1
A Phase II Study of MEDI4736 (Durvalumab) in Patients With Brain Metastasis From Epithelial-derived Tumors
A Phase II Study of MEDI4736 (Durvalumab) in Patients With Brain Metastasis From Epithelial-derived Tumors
Enrollment Status: Terminated
Publish Date: November 06, 2018
Intervention Type: Drug
Study Phase: Phase 2
Phase II Study of Everolimus in Patients With Advanced Solid Malignancies With TSC1, TSC2, NF1, NF2, or STK11 Mutations
Phase II Study of Everolimus in Patients With Advanced Solid Malignancies With TSC1, TSC2, NF1, NF2, or STK11 Mutations
Enrollment Status: Completed
Publish Date: October 02, 2018
Intervention Type: Drug
Study Phase: Phase 2
Genomic Landscape of EGFR Mutant NSCLC Prior to Afatinib and at the Time of Disease Progression Following Afatinib
Genomic Landscape of EGFR Mutant NSCLC Prior to Afatinib and at the Time of Disease Progression Following Afatinib
Enrollment Status: Terminated
Publish Date: March 05, 2018
Retrospective Analysis of Genomic Landscape of ALK Positive NSCLC Prior to Ceritinib, and at Disease Progression Following Ceritinib
Retrospective Analysis of Genomic Landscape of ALK Positive NSCLC Prior to Ceritinib, and at Disease Progression Following Ceritinib
Enrollment Status: Terminated
Publish Date: March 05, 2018
Phase I Study Combining MLN8237 With Nab-Paclitaxel in Patients With Advanced Solid Malignancies
Phase I Study Combining MLN8237 With Nab-Paclitaxel in Patients With Advanced Solid Malignancies
Enrollment Status: Completed
Publish Date: January 11, 2018
Intervention Type: Drug
Study Phase: Phase 1
View 36 Less Clinical Trials

131 Total Publications

Reply to: Delta-Like Ligand 3 Expression Across Lung Neuroendocrine Subtypes: Interpreting Response in Small Cell Lung Cancer and Beyond.
Reply to: Delta-Like Ligand 3 Expression Across Lung Neuroendocrine Subtypes: Interpreting Response in Small Cell Lung Cancer and Beyond.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: January 22, 2026
Similar Doctors
Expertise in
34
conditions
Dr. Nancy Bartlett
Oncology
Expertise in
34
conditions
Dr. Nancy Bartlett
Oncology

Washington University School Of Medicine

4921 Parkview Pl, 
Saint Louis, MO 
 (40.9 miles away)
314-362-7578
Languages Spoken:
English
See accepted insurances

Nancy Bartlett is an Oncologist in Saint Louis, Missouri. Dr. Bartlett is highly rated in 34 conditions, according to our data. Her top areas of expertise are Non-Hodgkin Lymphoma, Hodgkin Lymphoma, B-Cell Lymphoma, Bone Marrow Transplant, and Bone Marrow Aspiration.

Matthew Powell
Expertise in
22
conditions
Dr. Matthew Powell
Oncology
Expertise in
22
conditions
Dr. Matthew Powell
Oncology

Office

3023 N Ballas Rd Ste 450, 
Saint Louis, MO 
 (31.1 miles away)
314-996-6000
Languages Spoken:
English
See accepted insurances

Matthew Powell is an Oncologist in Saint Louis, Missouri. Dr. Powell is highly rated in 22 conditions, according to our data. His top areas of expertise are Endometrial Cancer, Ovarian Cancer, Cervical Cancer, Hysterectomy, and Oophorectomy.

Expertise in
16
conditions
Dr. Ramaswamy Govindan
Oncology
Expertise in
16
conditions
Dr. Ramaswamy Govindan
Oncology

Washington University School Of Medicine

4921 Parkview Pl, 
Saint Louis, MO 
 (40.9 miles away)
314-362-7578
Languages Spoken:
English
See accepted insurances

Ramaswamy Govindan is an Oncologist in Saint Louis, Missouri. Dr. Govindan is highly rated in 16 conditions, according to our data. His top areas of expertise are Lung Cancer, Non-Small Cell Lung Cancer (NSCLC), Small Cell Lung Cancer (SCLC), and Squamous Cell Lung Carcinoma.

Frequently Asked Questions about Dr. Daniel Morgensztern

How do I make an appointment with Dr. Daniel Morgensztern?

You can book an appointment with Dr. Daniel Morgensztern by calling their office at 314-286-2500. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Daniel Morgensztern a top-rated expert for Lung Cancer?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Daniel Morgensztern is classified as an Elite expert for Lung Cancer, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Daniel Morgensztern specialize in?

While Dr. Daniel Morgensztern is a Oncology, they have specific expertise in Lung Cancer, Non-Small Cell Lung Cancer (NSCLC), and Small Cell Lung Cancer (SCLC). MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Oncology.

Does Dr. Daniel Morgensztern participate in research or clinical trials?

Yes. Dr. Daniel Morgensztern has published 131 articles and abstracts on conditions like Lung Cancer. You can view a list of Dr. Daniel Morgensztern's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Daniel Morgensztern accept my insurance?

Dr. Daniel Morgensztern accepts most major insurance plans, including Aetna and Anthem BCBS. We recommend calling the office directly at 314-286-2500 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Morgensztern's expertise for a condition
ConditionClose
View All 11 Distinguished Conditions
View All 46 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile